VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

Suppr

超能文献

作者信息

Eagan R T, Ingle J N, Creagan E T, Frytak S, Kvols L K, Rubin J, McMachon R T

出版信息

Cancer Treat Rep. 1978 May;62(5):843-4.

PMID:657168

Abstract

摘要

相似文献

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

Cancer Treat Rep. 1978 May;62(5):843-4.

[A phase II study of oral VP-16 in primary lung cancer].

Gan To Kagaku Ryoho. 1985 Sep;12(9):1801-7.

[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].

Gan To Kagaku Ryoho. 1986 Jan;13(1):116-21.

Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2089-92.

[A phase II study of NK171 (etoposide)].

Gan To Kagaku Ryoho. 1985 Oct;12(10):2011-7.

Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.

Semin Oncol. 1985 Mar;12(1 Suppl 2):21-2.

Phase II trial of VP-16-213 in non-small-cell lung cancer.

Am J Clin Oncol. 1982 Feb;5(1):45-7.

Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Cancer Treat Rep. 1984 Dec;68(12):1513-4.

VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy.

Cancer Clin Trials. 1981;4(2):155-7.

[VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].

Schweiz Med Wochenschr. 1977 Jul 2;107(26):912-5.

引用本文的文献

VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.

Cancer Chemother Pharmacol. 1982;7(2-3):209-10. doi: 10.1007/BF00254551.

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC).

Cancer Chemother Pharmacol. 1982;7(2-3):205-7. doi: 10.1007/BF00254550.

VP16-213 (etoposide). A critical review of its activity.

Cancer Chemother Pharmacol. 1982;7(2-3):81-5. doi: 10.1007/BF00254526.

The podophyllotoxin derivatives VP16-213 and VM26.

Cancer Chemother Pharmacol. 1982;7(2-3):73-80. doi: 10.1007/BF00254525.

[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Klin Wochenschr. 1981 Nov 2;59(21):1177-88. doi: 10.1007/BF01721212.

cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma.

Cancer Chemother Pharmacol. 1983;11(1):35-7. doi: 10.1007/BF00257414.

Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Cancer Chemother Pharmacol. 1988;21(2):89-102. doi: 10.1007/BF00257354.

Combination chemotherapy for advanced adenocarcinoma of the lung. A review.

Cancer Chemother Pharmacol. 1988;21(2):103-16. doi: 10.1007/BF00257355.

Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.

Cancer Chemother Pharmacol. 1986;18 Suppl 2:S34-9. doi: 10.1007/BF00647449.

Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

J Natl Med Assoc. 1985 Oct;77(10):815-27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验